MA31910B1 - Antagonistes des recepteurs non steroidiens des mineralocorticoides derives de la 6h-dibenzo[b,e]oxepine - Google Patents
Antagonistes des recepteurs non steroidiens des mineralocorticoides derives de la 6h-dibenzo[b,e]oxepineInfo
- Publication number
- MA31910B1 MA31910B1 MA32909A MA32909A MA31910B1 MA 31910 B1 MA31910 B1 MA 31910B1 MA 32909 A MA32909 A MA 32909A MA 32909 A MA32909 A MA 32909A MA 31910 B1 MA31910 B1 MA 31910B1
- Authority
- MA
- Morocco
- Prior art keywords
- antagonists
- steroidial
- oxepine
- mineralocorticoids
- dibenzo
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- FPIWJQQRYHEICX-UHFFFAOYSA-N 6,11-dihydrobenzo[c][1]benzoxepine Chemical compound C1OC2=CC=CC=C2CC2=CC=CC=C12 FPIWJQQRYHEICX-UHFFFAOYSA-N 0.000 title 1
- 239000002395 mineralocorticoid Substances 0.000 title 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 title 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1477607P | 2007-12-19 | 2007-12-19 | |
| PCT/US2008/085997 WO2009085584A1 (en) | 2007-12-19 | 2008-12-09 | 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31910B1 true MA31910B1 (fr) | 2010-12-01 |
Family
ID=40430143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32909A MA31910B1 (fr) | 2007-12-19 | 2010-06-14 | Antagonistes des recepteurs non steroidiens des mineralocorticoides derives de la 6h-dibenzo[b,e]oxepine |
Country Status (33)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009018657A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| WO2010104721A1 (en) * | 2009-03-12 | 2010-09-16 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
| EP2568986B1 (en) | 2010-05-10 | 2016-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| EP2582365B1 (en) | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
| CN102060670A (zh) * | 2011-01-04 | 2011-05-18 | 常州大学 | 一种2-溴-6-氟苯甲醇的制备方法 |
| MD20150103A2 (ro) | 2013-05-02 | 2016-02-29 | Pfizer Inc. | Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10 |
| AR099416A1 (es) | 2014-02-28 | 2016-07-20 | Lilly Co Eli | Terapia combinada para la hipertensión resistente |
| ME03316B (me) | 2014-06-30 | 2019-10-20 | Astrazeneca Ab | Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora |
| JP2017531684A (ja) * | 2014-11-21 | 2017-10-26 | イーライ リリー アンド カンパニー | 腎障害の治療のための１，２−ベンゾチアゾール化合物 |
| US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| WO2018054357A1 (zh) * | 2016-09-24 | 2018-03-29 | 山东亨利医药科技有限责任公司 | 含盐皮质激素受体拮抗剂的药物组合物及其用途 |
| EP4118235B1 (en) | 2020-03-11 | 2026-08-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
| CN117510398A (zh) * | 2023-11-02 | 2024-02-06 | 上海诺丁太生物科技有限公司 | 一种高光学纯度(3r,4r)/(3s,4s)-n-boc-4-氨基-3-羟基哌啶的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072756A (en) * | 1973-05-17 | 1978-02-07 | Sandoz Ltd. | Tricyclo piperidino ketones and soporific compositions thereof |
| SE426341C (sv) * | 1980-02-14 | 1985-09-23 | Fagersta Ab | Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser |
| FR2603713B1 (fr) * | 1986-09-10 | 1992-07-24 | Canon Kk | Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant |
| US4999363A (en) * | 1988-06-09 | 1991-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| GB8914061D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| US5378701A (en) * | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
| US6372779B1 (en) | 1997-12-29 | 2002-04-16 | Ortho Pharmaceutical Corporation | Anti-inflammatory compounds |
| EP1154997A4 (en) | 1999-01-26 | 2002-11-04 | Dana Farber Cancer Inst Inc | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE |
| ES2260497T7 (es) * | 2001-11-21 | 2009-11-05 | Millennium Pharmaceuticals, Inc. | Antagonistas de receptores de quimioquininas y metodos de uso de los mismos. |
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| WO2005066153A1 (en) | 2003-12-19 | 2005-07-21 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| DE602004014640D1 (de) * | 2003-12-19 | 2008-08-07 | Lilly Co Eli | Tricyclische modulatoren von nuklearen steroidhormonrezeptoren |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| RU2007107177A (ru) * | 2004-07-28 | 2008-09-10 | Айрм Ллк (Bm) | Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов |
| SG161261A1 (en) | 2004-11-10 | 2010-05-27 | Incyte Corp | Lactam compounds and their use as pharmaceuticals |
| ES2375877T3 (es) | 2006-10-31 | 2012-03-07 | Pfizer Products Inc. | Compuestos de pirazolina como antagonistas de receptores de mineralocorticoides. |
| JP2010522732A (ja) | 2007-03-29 | 2010-07-08 | ナームローゼ・フエンノートチヤツプ・オルガノン | 鉱質コルチコイド受容体アンタゴニスト |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| WO2009094157A1 (en) | 2008-01-25 | 2009-07-30 | Arena Pharmaceuticals, Inc. | Dihydro- 1h- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists |
| WO2010104721A1 (en) | 2009-03-12 | 2010-09-16 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
-
2008
- 2008-12-02 TW TW097146779A patent/TWI431010B/zh not_active IP Right Cessation
- 2008-12-02 PE PE2008002008A patent/PE20091057A1/es not_active Application Discontinuation
- 2008-12-03 AR ARP080105263A patent/AR069554A1/es unknown
- 2008-12-03 CL CL2008003600A patent/CL2008003600A1/es unknown
- 2008-12-09 ES ES08866835T patent/ES2396605T3/es active Active
- 2008-12-09 CN CN200880121527.2A patent/CN101903377B/zh not_active Expired - Fee Related
- 2008-12-09 PT PT88668355T patent/PT2235007E/pt unknown
- 2008-12-09 MY MYPI20102867 patent/MY150474A/en unknown
- 2008-12-09 PL PL08866835T patent/PL2235007T3/pl unknown
- 2008-12-09 EP EP12185389.9A patent/EP2537845B1/en active Active
- 2008-12-09 EA EA201070762A patent/EA017668B1/ru not_active IP Right Cessation
- 2008-12-09 MX MX2010006911A patent/MX2010006911A/es active IP Right Grant
- 2008-12-09 BR BRPI0820805-0A patent/BRPI0820805A2/pt not_active IP Right Cessation
- 2008-12-09 UA UAA201007627A patent/UA100131C2/uk unknown
- 2008-12-09 EP EP08866835A patent/EP2235007B1/en active Active
- 2008-12-09 RS RS20120541A patent/RS52594B/sr unknown
- 2008-12-09 JP JP2010539618A patent/JP5562866B2/ja not_active Expired - Fee Related
- 2008-12-09 WO PCT/US2008/085997 patent/WO2009085584A1/en not_active Ceased
- 2008-12-09 AU AU2008343524A patent/AU2008343524B2/en not_active Ceased
- 2008-12-09 SI SI200830852T patent/SI2235007T1/sl unknown
- 2008-12-09 CA CA2710409A patent/CA2710409C/en not_active Expired - Fee Related
- 2008-12-09 KR KR1020107013601A patent/KR101254382B1/ko not_active Expired - Fee Related
- 2008-12-09 HR HRP20120916AT patent/HRP20120916T1/hr unknown
- 2008-12-09 NZ NZ586300A patent/NZ586300A/en not_active IP Right Cessation
- 2008-12-09 DK DK08866835.5T patent/DK2235007T3/da active
- 2008-12-09 US US12/330,539 patent/US7994164B2/en not_active Expired - Fee Related
- 2008-12-09 ES ES12185389.9T patent/ES2459318T3/es active Active
-
2010
- 2010-06-14 MA MA32909A patent/MA31910B1/fr unknown
- 2010-06-14 IL IL206353A patent/IL206353A/en not_active IP Right Cessation
- 2010-06-15 ZA ZA2010/04257A patent/ZA201004257B/en unknown
- 2010-06-16 CO CO10072532A patent/CO6300953A2/es not_active Application Discontinuation
- 2010-06-17 GT GT201000179A patent/GT201000179A/es unknown
- 2010-06-17 EC EC2010010266A patent/ECSP10010266A/es unknown
- 2010-06-17 DO DO2010000185A patent/DOP2010000185A/es unknown
- 2010-06-18 TN TN2010000292A patent/TN2010000292A1/fr unknown
-
2012
- 2012-07-17 EC ECSP12012048 patent/ECSP12012048A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2010000292A1 (en) | 6h-dibenzo[b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists | |
| WO2008060907A3 (en) | Pyrrolo-pyridine kinase inhibitors | |
| MA29772B1 (fr) | Benzimidazoles substitues et procedes de preparation | |
| MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA30221B1 (fr) | Aryldihydro-isoquinoléinones substituées par un azacyclyle, procédé pour leur préparation et leur utilisation en tant que médicaments | |
| MA31699B1 (fr) | Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3 | |
| MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
| MA30991B1 (fr) | Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| TN2010000107A1 (fr) | Derives d'azacyclylisoquinolinone et isoindolinone servant d'antagonistes du recepteur d'histamine -3 | |
| MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
| TNSN07305A1 (fr) | Agonistes de pyy et leurs utilisations | |
| MA30950B1 (fr) | Nouveaux (aza) cyclohexanes carbonyles en tant que ligands du recepteur de dopamine d3. | |
| MA31574B1 (fr) | Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
| WO2008007211A8 (en) | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds | |
| EP2289891A3 (fr) | Nouveaux dérivés de polyquinoléines et leur utilisation thérapeutique. | |
| MA32506B1 (fr) | Nouveaux composes | |
| MA33132B1 (fr) | Derives pyrazole utilises comme antagonistes du recepteur ccr4 | |
| MA30798B1 (fr) | Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1 | |
| MA32191B1 (fr) | Inhibiteurs du recepteur de chimiokine cxcr3 | |
| EP1864649A3 (fr) | Composé de type bis-urée, composition le comprenant, utilisation et procédé de traitement cosmétique | |
| GB0510143D0 (en) | Novel compounds A1 |